Trial Profile
An Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY2287411 Injection, in Patients With Solid Tumors Known to Express Mesothelin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Thorium (Th227)-anetumab corixetan (Primary)
- Indications Adenocarcinoma; Mesothelioma; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 08 Apr 2022 Status changed from active, no longer recruiting to completed.
- 16 Sep 2021 Planned primary completion date changed from 11 Aug 2021 to 30 Sep 2021.
- 16 Jul 2021 Planned primary completion date changed from 30 Jun 2021 to 11 Aug 2021.